BIP Wealth LLC Invests $532,000 in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

BIP Wealth LLC purchased a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,283 shares of the specialty pharmaceutical company's stock, valued at approximately $532,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Versant Capital Management Inc raised its holdings in Jazz Pharmaceuticals by 9.4% in the 1st quarter. Versant Capital Management Inc now owns 1,058 shares of the specialty pharmaceutical company's stock valued at $131,000 after buying an additional 91 shares during the last quarter. Bessemer Group Inc. raised its holdings in Jazz Pharmaceuticals by 0.3% during the 4th quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company's stock worth $3,317,000 after purchasing an additional 92 shares during the last quarter. Kendall Capital Management raised its holdings in Jazz Pharmaceuticals by 1.2% during the 1st quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company's stock worth $989,000 after purchasing an additional 95 shares during the last quarter. Synovus Financial Corp raised its holdings in Jazz Pharmaceuticals by 0.5% during the 4th quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company's stock worth $2,365,000 after purchasing an additional 100 shares during the last quarter. Finally, Quarry LP raised its holdings in Jazz Pharmaceuticals by 6.3% during the 4th quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company's stock worth $209,000 after purchasing an additional 100 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $116.35, for a total transaction of $116,350.00. Following the completion of the transaction, the chief executive officer owned 439,307 shares of the company's stock, valued at $51,113,369.45. The trade was a 0.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Seamus Mulligan bought 100,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, May 9th. The shares were bought at an average cost of $98.26 per share, with a total value of $9,826,000.00. Following the acquisition, the director directly owned 100,000 shares in the company, valued at approximately $9,826,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 2,500 shares of company stock valued at $277,930 in the last ninety days. Insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock traded up $3.78 during midday trading on Wednesday, reaching $116.08. The stock had a trading volume of 983,291 shares, compared to its average volume of 831,798. The company has a quick ratio of 2.97, a current ratio of 3.38 and a debt-to-equity ratio of 1.28. The firm has a market capitalization of $7.02 billion, a PE ratio of 15.48, a P/E/G ratio of 4.81 and a beta of 0.32. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $148.06. The firm's 50-day moving average price is $108.50 and its 200 day moving average price is $118.40.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The company had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The firm's quarterly revenue was down .5% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.68 EPS. As a group, research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on JAZZ. Piper Sandler restated an "overweight" rating and set a $147.00 price target (down previously from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Wall Street Zen downgraded shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft started coverage on Jazz Pharmaceuticals in a research note on Tuesday. They set a "buy" rating and a $152.00 price objective on the stock. Robert W. Baird dropped their price objective on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Finally, Royal Bank Of Canada lowered their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $181.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.